Navigation Links
Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
Date:1/16/2008

MENLO PARK, Calif., Jan. 16 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that dosing has begun in a clinical study to confirm the full antiplatelet activity of its novel combination medicine CGT-2168. CGT-2168 is a once-daily capsule that combines clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) with a gastroprotectant (omeprazole) to improve the gastrointestinal safety of antiplatelet therapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO)

The crossover study (CG106) will characterize the pharmacodynamic effects of CGT-2168 compared with Plavix and will expand earlier findings of comparability. "In a previous clinical trial we demonstrated that the absorption of CGT-2168 is equivalent to that of Plavix, and that the omeprazole component within CGT-2168 does not interfere with the metabolism of the clopidogrel component," said Cogentus Chairman and Chief Executive Officer Mark A. Goldsmith, M.D., Ph.D.

An independent study published this week in the Journal of the American College of Cardiology showed that commercially available omeprazole significantly decreases the antiplatelet activity of Plavix when the two medicines are co-administered. "This finding is consistent with our own earlier clinical data that revealed an adverse drug interaction between Plavix and Prilosec(R) (marketed omeprazole), and may raise serious concerns for patients and practitioners," Dr. Goldsmith said. "However, these findings contrast with the properties we have observed with our unique formulation, CGT-2168. We expect the CG106 trial to confirm that CGT-2168 exhibits full antiplatelet activity and avoids the drug-drug interaction reported with the individual drugs on the market today."

Separately, Cogentus has begun COGENT-1, a global Phase 3 trial that will evaluate the clinical benefits
'/>"/>

SOURCE Cogentus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
2. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015 LifeScienceIndustryResearch.com ... Research Report on Global and China Lysine Industry ... a professional and the deep research report in ... Lysine basic information including definition, classification specifications, application, ... US, Europe , ...
(Date:4/17/2015)... 17, 2015 CVS Health Corporation (NYSE: ... Friday, May 1, 2015, at 8:30 a.m. (EDT) with ... results. An audio webcast of the conference ... portion of the CVS Health website for all interested ... This webcast will be archived and available on the ...
(Date:4/17/2015)... , April 17, 2015  Trovagene, Inc., ... announced today that clinical data presented at the ... its urine-based Precision Cancer Monitoring ℠ (PCM) ... monitoring of EGFR T790M mutations in ... Detection of EGFR T790M Mutation in Urinary Circulating ...
Breaking Medicine Technology:Lysine Market International (US, Europe, Japan) Research Analysis 2Lysine Market International (US, Europe, Japan) Research Analysis 3Lysine Market International (US, Europe, Japan) Research Analysis 4Lysine Market International (US, Europe, Japan) Research Analysis 5Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
... 2011 Visionary Pharmaceuticals, Inc., announced today that ... a consortium of Angel Investors. The company is ... retinoic acid related orphan receptor (ROR) modulators targeting ... disorders including rheumatoid arthritis, multiple sclerosis, psoriasis and ...
... Ind., July 26, 2011 Symmetry Medical Inc. (NYSE: ... the global orthopaedic device industry and other medical markets, announced ... for the period ending July 2, 2011 before the market ... an accompanying conference call at 8:00 a.m. ET on Thursday, ...
Cached Medicine Technology:Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities 2Symmetry Medical to Report Second Quarter 2011 Financial Results on August 4, 2011 2
(Date:4/17/2015)... April 17, 2015 Alcohol and Violence ... (NCADD) notes that drinking and driving has been the ... the same time, the link between alcohol and crime ... abuse and violence and sexual assault, and their relationship ... the NCADD, 5.3 million adults in America were drinking ...
(Date:4/17/2015)... From the day Dr. Todd Phillips founded The ... has empowered young people to create meaningful change in their ... water and the Gospel to all of Liberia by 2020 ... and 27, students, faculty and staff raised $21,000 through the ... and the Good News of Jesus. , During the ...
(Date:4/17/2015)... Representatives Jim Himes (D-CT) and Ed ... HR 1849 in congress on April 16, 2015 in ... patients with the genetic disease. , The bill, ... the first to create a federally led and financed ... hemorrhagic telangiectasia. This would effectively prevent premature death and ...
(Date:4/17/2015)... At the end of February 2015, Choices Recovery ... the Oscars” in the Stardust Penthouse on the rooftop ... Los Angeles skyline. These events honoring the 2015 Oscar ... producer of sustainable product placement in TV and film. ... of eco-friendly and socially conscious products and services, the ...
(Date:4/17/2015)... Baptist Health and The University of Texas ... designed to transform oncology care in northeast Florida and ... create a joint cancer program to enhance patient access ... MD Anderson Cancer Center is anticipated to open in ... highly coordinated, multidisciplinary cancer care for adults in the ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3
... with first product sales since 2005, SEATTLE, May ... reported financial results for the quarter ended,March 31, 2008. ... $20,000 for the first quarter of 2007. Gross product ... first quarter of 2008., Total operating expenses increased ...
... Holdings, Inc. ("Holdings",or the "Company"), the parent company ... nation,s largest cancer services companies, reported revenue of,$810.6 ... cash flow of,$50.9 million for the quarter ended ... include those of US Oncology, its wholly-owned,subsidiary, through ...
... CorVel Corporation,(Nasdaq: CRVL ) announced today that Gordon ... Bank of America 2008 Health Care Services,Conference on Tuesday, ... be,held at the Four Seasons Hotel in Las Vegas, ... through a webcast on,CorVel,s website, http://www.corvel.com . To ...
... result of San Diego State,University,s interim suspension ... supports the decisions of our,member fraternities to ... parties accountable for their actions. The NIC, ... with our member organizations and San,Diego State ...
... Inter-Con Security Officers Report They Don,t Have Healthcare, ... OAKLAND, Calif., May 7 In the ... increasing,number of security officers report they either don,t ... their families., Kaiser contractor Inter-Con Security is ...
... ALEXANDRIA, Va., May 7 The American Physical,Therapy ... coalition of,health and consumer groups to advocate for ... Safety of Seniors Act., In remarks during ... and National Falls Free Coalition representative Bonita,Lynn Beattie, ...
Cached Medicine News:Health News:Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results 2Health News:Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results 3Health News:Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results 4Health News:Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results 5Health News:Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results 6Health News:US Oncology Reports First Quarter 2008 Results 2Health News:US Oncology Reports First Quarter 2008 Results 3Health News:US Oncology Reports First Quarter 2008 Results 4Health News:US Oncology Reports First Quarter 2008 Results 5Health News:US Oncology Reports First Quarter 2008 Results 6Health News:US Oncology Reports First Quarter 2008 Results 7Health News:US Oncology Reports First Quarter 2008 Results 8Health News:US Oncology Reports First Quarter 2008 Results 9Health News:US Oncology Reports First Quarter 2008 Results 10Health News:US Oncology Reports First Quarter 2008 Results 11Health News:US Oncology Reports First Quarter 2008 Results 12Health News:US Oncology Reports First Quarter 2008 Results 13Health News:US Oncology Reports First Quarter 2008 Results 14Health News:US Oncology Reports First Quarter 2008 Results 15Health News:US Oncology Reports First Quarter 2008 Results 16Health News:US Oncology Reports First Quarter 2008 Results 17Health News:CorVel Announces Appearance at Bank of America Health Care Conference 2Health News:Workers With No Healthcare Protecting Kaiser Facilities, Security Contractor May Be Misleading California's Largest Healthcare Provider 2Health News:Physical Therapist Stresses Funding for Falls Prevention at National Safety Council Briefing 2
For injecting viscoelastic to all meridians of the anterior chamber and to coat intraocular lenses. 27G x 7/8in (.40 x 22mm), angled 10mm from end....
Cannula tip is specially rounded, extra smooth for safe insertion through wound and manipulation in the anterior chamber. 27G x 7/8 in (.40 x 22mm)....
For injecting anesthetics into the muscle cone. 23G x 1 1/2 in (.60 x 38mm)...
... (Electronystagmography) is a complete vestibular diagnostic ... eye movements collected via electrodes. Its ... to use. Saccade, tracking and Slow ... interpretation is facilitated by graphic comparison ...
Medicine Products: